Literature DB >> 12870559

Representative payeeship and mental illness: a review.

Daniel J Luchins1, David L Roberts, Patricia Hanrahan.   

Abstract

Representative Payeeship (RP) is intended to help individuals who are unable to manage disability payments appropriately to meet their basic living needs. This paper reviews the literature on whether RP is effective among individuals with mental disorders. We also review RP's mental health effects and its use as leverage in achieving behavioral goals. RP appears to be effective in helping clients meet their basic living needs; it also may decrease hospitalization and improve treatment compliance. Finally, we propose a research design to disentangle the role of clinical leverage from the more basic money-management function of RP.

Entities:  

Mesh:

Year:  2003        PMID: 12870559     DOI: 10.1023/a:1024089317630

Source DB:  PubMed          Journal:  Adm Policy Ment Health        ISSN: 0894-587X


  5 in total

1.  Financial capacity in persons with schizophrenia and serious mental illness: clinical and research ethics aspects.

Authors:  Daniel C Marson; Robert Savage; Jacqueline Phillips
Journal:  Schizophr Bull       Date:  2005-11-17       Impact factor: 9.306

2.  Impact of decisional capacity on the use of leverage to encourage treatment adherence.

Authors:  Paul S Appelbaum; Allison Redlich
Journal:  Community Ment Health J       Date:  2006-04

3.  All-data approach to assessing financial capability in people with psychiatric disabilities.

Authors:  Christina M Lazar; Anne C Black; Thomas J McMahon; Robert A Rosenheck; Richard Ries; Donna Ames; Marc I Rosen
Journal:  Psychol Assess       Date:  2015-07-06

4.  Financial Capability: Clinicians' Assessment of Beneficiaries With Dual Diagnoses.

Authors:  Thomas A Thornhill Iv; Anne C Black; Marc I Rosen
Journal:  J Dual Diagn       Date:  2019-02-13

5.  Patients with schizophrenia and their finances: how they spend their money.

Authors:  Laurence Borras; Sylvia Mohr; Maria Boucherie; Sophie Dupont-Willemin; François Ferrero; Philippe Huguelet
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-09-27       Impact factor: 4.328

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.